Action NBIX NEUROCRINE BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Neurocrine Biosciences, Inc.

Actions

NBIX

US64125C1099

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
136 USD -1,28% Graphique intraday de Neurocrine Biosciences, Inc. +3,02% +3,21%
24/04 NEUROCRINE BIOSCIENCES, INC. : Wells Fargo Securities relève à l'achat ZM
24/04 Neurocrine Biosciences, Inc. lance l'initiative éducative What the C@H ! pour soutenir la communauté de l'hyperplasie congénitale des surrénales CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Neurocrine Biosciences Launches WHAT THE C@H Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Investor Conferences in March
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NBIX
  4. Actualités Neurocrine Biosciences, Inc.
  5. Autres langues